成年人的药理治疗成年人的药理治疗
Torbjörn Tomson1, Johan Zelano2,3,4, Yew Li Dang5,6
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
概括
选择合适的药需要个性化风险效益分析. 诸如类型,患者特征和药物副作用等因素指导抗发作药物的选择和剂量.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 治疗涉及到关于启动和选择抗发作药物的复杂决策.
- 有超过25种ASM可用,允许根据个体患者的需要和的特征制定量身定制的治疗策略.
研究的目的:
- 提供对影响症药物治疗决策的关键因素的全面概述.
- 引导临床医生选择合适的ASM,确定最佳剂量,并管理治疗挑战.
主要方法:
- 审查目前治疗的药理学方法.
- 讨论影响ASM选择的因素,包括类型,疗效,患者人口统计,并发症和药物特异性.
- 考虑剂量策略,治疗药物监测和治疗耐药性的管理.
主要成果:
- 选择ASM取决于的类型,ASM疗效谱,年龄,性别,并发症,并发药物,副作用易感性,成本和患者偏好.
- 缓慢的定位和寻求最低有效剂量是最好的,以获得最佳的耐受性和反应.
- 治疗失败需要排除错误诊断,不坚持和低于最佳剂量,然后再考虑替代疗法,如添加ASM或非药物选择.
结论:
- 个性化风险效益分析对于的所有治疗决策至关重要,从最初的药物选择到戒断.
- 优化ASM治疗需要仔细考虑多种患者特异性因素,并遵守推的剂量和管理策略.
- 对于耐药性,在优化药理干预后,探索替代治疗方式至关重要.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
427
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
427
Antiepileptic Drugs: Sodium Channel Blockers
686
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
686
Epilepsy and Seizures: Overview
217
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
217
Antiepileptic Drugs: GABAergic Pathway Potentiators
467
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
467
Antiepileptic Drugs: Calcium Channel Blockers
468
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
468
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
350
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
350


